Jin Chu1, Domenico Praticò. 1. Department of Pharmacology, Temple University, Philadelphia, PA, USA.
Abstract
OBJECTIVE: The 5-lipoxygenase (5-LO) enzymatic pathway is widely distributed within the central nervous system, and is upregulated in Alzheimer's disease. However, the mechanism whereby it may influence the disease pathogenesis remains elusive. METHODS: We evaluated the molecular mechanism by which 5-LO regulates amyloid β (Aβ) formation in vitro and in vivo by pharmacological and genetic approaches. RESULTS: Here we show that 5-LO regulates the formation of Aβ by activating the cAMP-response element binding protein (CREB), which in turn increases transcription of the γ-secretase complex. Preventing CREB activation by pharmacologic inhibition or dominant negative mutants blocks the 5-LO-dependent elevation of Aβ formation and the increase of γ-secretase mRNA and protein levels. Moreover, 5-LO targeted gene disruption or its in vivo selective pharmacological inhibition results in a significant reduction of Aβ, CREB and γ-secretase levels. INTERPRETATION: These data establish a novel functional role for 5-LO in regulating endogenous formation of Aβ levels in the central nervous system. Thus, 5-LO pharmacological inhibition may be beneficial in the treatment and prevention of Alzheimer's disease.
OBJECTIVE: The 5-lipoxygenase (5-LO) enzymatic pathway is widely distributed within the central nervous system, and is upregulated in Alzheimer's disease. However, the mechanism whereby it may influence the disease pathogenesis remains elusive. METHODS: We evaluated the molecular mechanism by which 5-LO regulates amyloid β (Aβ) formation in vitro and in vivo by pharmacological and genetic approaches. RESULTS: Here we show that 5-LO regulates the formation of Aβ by activating the cAMP-response element binding protein (CREB), which in turn increases transcription of the γ-secretase complex. Preventing CREB activation by pharmacologic inhibition or dominant negative mutants blocks the 5-LO-dependent elevation of Aβ formation and the increase of γ-secretase mRNA and protein levels. Moreover, 5-LO targeted gene disruption or its in vivo selective pharmacological inhibition results in a significant reduction of Aβ, CREB and γ-secretase levels. INTERPRETATION: These data establish a novel functional role for 5-LO in regulating endogenous formation of Aβ levels in the central nervous system. Thus, 5-LO pharmacological inhibition may be beneficial in the treatment and prevention of Alzheimer's disease.
Authors: Domenico Praticò; Victoria Zhukareva; Yuemang Yao; Kunihiro Uryu; Colin D Funk; John A Lawson; John Q Trojanowski; Virginia M-Y Lee Journal: Am J Pathol Date: 2004-05 Impact factor: 4.307
Authors: William J Netzer; Fei Dou; Dongming Cai; Darren Veach; Stephanie Jean; Yueming Li; William G Bornmann; Bayard Clarkson; Huaxi Xu; Paul Greengard Journal: Proc Natl Acad Sci U S A Date: 2003-10-01 Impact factor: 11.205
Authors: J Chu; J-G Li; P F Giannopoulos; B E Blass; W Childers; M Abou-Gharbia; D Praticò Journal: Mol Psychiatry Date: 2015-01-06 Impact factor: 15.992